Oncology

Cell membrane lipid phosphatidylserine (PS) is abnormally exposed on the surface of cancer cells, allowing tumour cells to evade the normal immune response. New Path is developing molecules that bind to PS as a targeting technology for delivery of drug conjugates to cancer cells.

Antibacterials

Lanthipeptides are known to have excellent activity against gram positive bacteria through binding to lipid II in the bacterial cell membrane. New Path have collaborated with Public Health England to identify novel semi-synthetic lanthipetides which have activity against key ESKAPE pathogens.